iX Biopharma (SGX:42C) Total Operating Expense: S$4.22 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:42C iX Biopharma Ltd SGX:42C
36 GF Score
Price S$0.55
GF Value S$0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is iX Biopharma Total Operating Expense?

iX Biopharma SGX:42C -0.91% 36 Total Operating Expense is S$4.22 Mil as of Mar. 2026. GuruFocus rates SGX:42C with a GF Score™ of 36/100 and a GF Value™ of S$0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

iX Biopharma's Total Operating Expense for the three months ended in Mar. 2026 was S$2.48 Mil. iX Biopharma's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was S$4.22 Mil.

iX Biopharma Total Operating Expense Related Terms

iX Biopharma Total Operating Expense Historical Data

* Premium members only.

The historical data trend for iX Biopharma's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iX Biopharma Total Operating Expense Chart

iX Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.70 11.05 10.73 7.93 8.09

iX Biopharma Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.16 1.75 0.00 2.48
SGX:42C
36GF Score
iX Biopharma Ltd SGX:42C
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iX Biopharma Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was S$4.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of S$4.22 Mil mean?
iX Biopharma (SGX:42C) has a Total Operating Expense of S$4.22 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on iX Biopharma and its competitors.
Is iX Biopharma's Total Operating Expense too high?
iX Biopharma's current Total Operating Expense is S$4.22 Mil. Overall, iX Biopharma has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iX Biopharma's Total Operating Expense compare to ZTS and UTHR?
iX Biopharma's Total Operating Expense of S$4.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on iX Biopharma and its competitors. iX Biopharma's current Total Operating Expense is S$4.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iX Biopharma stock overvalued right now?
Based on GuruFocus' analysis, iX Biopharma (SGX:42C) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.03, compared to a current price of S$0.55 — trading 1716.7% above its estimated fair value. The current Total Operating Expense is S$4.22 Mil. iX Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For iX Biopharma (SGX:42C), the current Total Operating Expense is S$4.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iX Biopharma (SGX:42C) Overvalued in 2026?

Based on GuruFocus' analysis, iX Biopharma stock appears to be overvalued. The current stock price of S$0.55 is trading 1716.7% above its estimated GF Value™ of S$0.03. GuruFocus considers iX Biopharma to be Significantly Overvalued.

Key valuation signals for SGX:42C:

  • Total Operating Expense: S$4.22 Mil
  • GF Value™: S$0.03 vs. price of S$0.55 (1716.7% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the SGX:42C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iX Biopharma Business Description

Address 1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
36GF Score

Get the complete analysis for SGX:42C

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.55
Price
S$0.03
GF Value